Applications of extracorporeal photochemotherapy in 'non-oncological' diseases

R. Dall'Amico, F. Zulian, G. Montini, B. Andretta, L. Murer, F. Rossetti, U. Livi, G. Zacchello, F. Zacchello

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Photopheresis (ECP) is a new therapy for oncological and autoimmune diseases consisting in the reinfusion of 3-9 x 109 leukocytes, taken from the patient by leukapheresis, and treated in an extracorporeal system with 8- methoxypsoralen and ultraviolet light A. Nine patients affected by T cell immunomediated diseases (2 scleroderma, 1 chronic GVHD, 1 polyarteritis, 1 rheumatoid arthritis and 4 heart transplant patients with numerous episodes of acute rejection) were treated with ECP. Photopheresis was performed on 2 consecutive days every 3-4 weeks. All patients affected by autoimmune diseases experienced an improvement during treatment with ECP. In 2 of the 4 patients with heart transplant, rejection was reversed by photopheresis. No major side effects were observed during the treatment. In conclusion ECP is a safe and well tolerated therapy. Although the number of patients is small ECP seems to be an effective modality in many diseases.

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalInternational Journal of Artificial Organs
Volume16
Issue numberSUPPL. 5
Publication statusPublished - 1993

Fingerprint

Photopheresis
Transplants
Methoxsalen
Autoimmune Diseases
T-cells
Leukapheresis
Graft Rejection
Therapeutics
Ultraviolet Rays
Rheumatoid Arthritis
Leukocytes
T-Lymphocytes

ASJC Scopus subject areas

  • Biophysics

Cite this

Dall'Amico, R., Zulian, F., Montini, G., Andretta, B., Murer, L., Rossetti, F., ... Zacchello, F. (1993). Applications of extracorporeal photochemotherapy in 'non-oncological' diseases. International Journal of Artificial Organs, 16(SUPPL. 5), 168-172.

Applications of extracorporeal photochemotherapy in 'non-oncological' diseases. / Dall'Amico, R.; Zulian, F.; Montini, G.; Andretta, B.; Murer, L.; Rossetti, F.; Livi, U.; Zacchello, G.; Zacchello, F.

In: International Journal of Artificial Organs, Vol. 16, No. SUPPL. 5, 1993, p. 168-172.

Research output: Contribution to journalArticle

Dall'Amico, R, Zulian, F, Montini, G, Andretta, B, Murer, L, Rossetti, F, Livi, U, Zacchello, G & Zacchello, F 1993, 'Applications of extracorporeal photochemotherapy in 'non-oncological' diseases', International Journal of Artificial Organs, vol. 16, no. SUPPL. 5, pp. 168-172.
Dall'Amico R, Zulian F, Montini G, Andretta B, Murer L, Rossetti F et al. Applications of extracorporeal photochemotherapy in 'non-oncological' diseases. International Journal of Artificial Organs. 1993;16(SUPPL. 5):168-172.
Dall'Amico, R. ; Zulian, F. ; Montini, G. ; Andretta, B. ; Murer, L. ; Rossetti, F. ; Livi, U. ; Zacchello, G. ; Zacchello, F. / Applications of extracorporeal photochemotherapy in 'non-oncological' diseases. In: International Journal of Artificial Organs. 1993 ; Vol. 16, No. SUPPL. 5. pp. 168-172.
@article{124311468f474adcb1c243dd044f22f3,
title = "Applications of extracorporeal photochemotherapy in 'non-oncological' diseases",
abstract = "Photopheresis (ECP) is a new therapy for oncological and autoimmune diseases consisting in the reinfusion of 3-9 x 109 leukocytes, taken from the patient by leukapheresis, and treated in an extracorporeal system with 8- methoxypsoralen and ultraviolet light A. Nine patients affected by T cell immunomediated diseases (2 scleroderma, 1 chronic GVHD, 1 polyarteritis, 1 rheumatoid arthritis and 4 heart transplant patients with numerous episodes of acute rejection) were treated with ECP. Photopheresis was performed on 2 consecutive days every 3-4 weeks. All patients affected by autoimmune diseases experienced an improvement during treatment with ECP. In 2 of the 4 patients with heart transplant, rejection was reversed by photopheresis. No major side effects were observed during the treatment. In conclusion ECP is a safe and well tolerated therapy. Although the number of patients is small ECP seems to be an effective modality in many diseases.",
author = "R. Dall'Amico and F. Zulian and G. Montini and B. Andretta and L. Murer and F. Rossetti and U. Livi and G. Zacchello and F. Zacchello",
year = "1993",
language = "English",
volume = "16",
pages = "168--172",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Applications of extracorporeal photochemotherapy in 'non-oncological' diseases

AU - Dall'Amico, R.

AU - Zulian, F.

AU - Montini, G.

AU - Andretta, B.

AU - Murer, L.

AU - Rossetti, F.

AU - Livi, U.

AU - Zacchello, G.

AU - Zacchello, F.

PY - 1993

Y1 - 1993

N2 - Photopheresis (ECP) is a new therapy for oncological and autoimmune diseases consisting in the reinfusion of 3-9 x 109 leukocytes, taken from the patient by leukapheresis, and treated in an extracorporeal system with 8- methoxypsoralen and ultraviolet light A. Nine patients affected by T cell immunomediated diseases (2 scleroderma, 1 chronic GVHD, 1 polyarteritis, 1 rheumatoid arthritis and 4 heart transplant patients with numerous episodes of acute rejection) were treated with ECP. Photopheresis was performed on 2 consecutive days every 3-4 weeks. All patients affected by autoimmune diseases experienced an improvement during treatment with ECP. In 2 of the 4 patients with heart transplant, rejection was reversed by photopheresis. No major side effects were observed during the treatment. In conclusion ECP is a safe and well tolerated therapy. Although the number of patients is small ECP seems to be an effective modality in many diseases.

AB - Photopheresis (ECP) is a new therapy for oncological and autoimmune diseases consisting in the reinfusion of 3-9 x 109 leukocytes, taken from the patient by leukapheresis, and treated in an extracorporeal system with 8- methoxypsoralen and ultraviolet light A. Nine patients affected by T cell immunomediated diseases (2 scleroderma, 1 chronic GVHD, 1 polyarteritis, 1 rheumatoid arthritis and 4 heart transplant patients with numerous episodes of acute rejection) were treated with ECP. Photopheresis was performed on 2 consecutive days every 3-4 weeks. All patients affected by autoimmune diseases experienced an improvement during treatment with ECP. In 2 of the 4 patients with heart transplant, rejection was reversed by photopheresis. No major side effects were observed during the treatment. In conclusion ECP is a safe and well tolerated therapy. Although the number of patients is small ECP seems to be an effective modality in many diseases.

UR - http://www.scopus.com/inward/record.url?scp=0027879211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027879211&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 168

EP - 172

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - SUPPL. 5

ER -